 |
|
|
|
 |
A Study of Ofatumumab plus DHAP Chemotherapy in Relapsed or Refractory Aggressive Lymphoma
[Protocol 09-082]
- Full Title :
- A SINGLE ARM, SAFETY AND EFFICACY STUDY OF OFATUMUMAB IN COMBINATION WITH ICE OR DHAP CHEMOTHERAPY IN RELAPSED OR REFRACTORY AGGRESSIVE LYMPHOMA PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANTATION
- Purpose :
The purpose of this study is to evaluate the safety and effectiveness of an investigational drug called ofatumumab when given with chemotherapy in patients with diffuse large B-cell lymphoma or transformed follicular lymphoma that persists or relapses despite prior chemotherapy.
Ofatumumab is an antibody that binds to lymphoma cells and results in lymphoma cell death. Patients in this study will receive ofatumumab plus DHAP (dexamethasone, cytarabine, and cisplatin) chemotherapy. The study will evaluate the effectiveness of this combination therapy both for treating lymphoma and for enabling patients to receive additional treatment with autologous stem cell transplantation.
- Eligibility :
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have CD20-positive diffuse large B-cell lymphoma or transformed follicular lymphoma that persists despite prior chemotherapy which included rituximab and an anthracycline drug.
- At least 4 weeks must have passed since completion of prior therapy and entry into the study.
- Patients must be eligible for transplantation.
- Patients must not be confined to a bed or chair for more than half of their normal waking hours.
- Patients must be age 18 or older
For more information and to inquire about eligibility for this study, please contact Dr. Matthew Matasar at 212-639-8889.
|
|
|
|
|
